Ultragenyx Pharmaceutical Inc. RARE

NAS: RARE | ISIN: US90400D1081   6/10/2026
14,46 USD (-0,28%)
(-0,28%)   6/10/2026

2 oktober 2026 · Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) · Persbericht

3 april 2026 · DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026 · Persbericht

1 april 2026 · Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Ultragenyx Lawsuit - RARE · Persbericht

28 maart 2026 · Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

25 maart 2026 · Lost Money on Ultragenyx Pharmaceutical Inc.(RARE)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky · Persbericht

19 maart 2026 · INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law · Persbericht

18 maart 2026 · LEVI & KORSINSKY, LLP: FRAUD-ON-THE-MARKET DOCTRINE UNDERPINS ULTRAGENYX PHARMACEUTICAL SECURITIES CLASS ACTION · Persbericht

16 maart 2026 · RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 · Persbericht

14 maart 2026 · Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

13 maart 2026 · DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit · Persbericht

11 maart 2026 · RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 · Persbericht

11 maart 2026 · LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION · Persbericht

6 maart 2026 · RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 · Persbericht

4 maart 2026 · Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law · Persbericht

4 maart 2026 · LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE · Persbericht

2 maart 2026 · Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP · Persbericht

28 februari 2026 · Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

27 februari 2026 · RARE SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 · Persbericht

27 februari 2026 · Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RARE · Persbericht

25 februari 2026 · LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION · Persbericht

Mijn selecties